{"id":14735,"date":"2020-09-11T17:10:45","date_gmt":"2020-09-11T04:10:45","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=14735"},"modified":"2020-09-11T17:10:45","modified_gmt":"2020-09-11T04:10:45","slug":"targeted-molecular-therapies-for-the-treatment-of-chronic-lymphocytic-leukemia","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=14735","title":{"rendered":"Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″]<\/p>\n

Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia<\/h1>\n

<\/h2>\n

[\/vc_custom_heading][vc_column_text]This article was originally published by Hematology Advisor\u00a0<\/a><\/p>\n

Chronic lymphocytic leukemia (CLL) presents as an accumulation of monoclonal, mature, CD5+ B-cells in secondary lymphatic organs where cancer cells engage in molecular and cellular interactions disrupting the adaptive immune response. Promising advances in therapy options for patients with CLL, targeting these molecular interactions, were discussed in a review published in\u00a0The New England Journal of Medicine<\/em>.1<\/sup><\/p>\n

Since the introduction of these novel therapeutics, the use of chemoimmunotherapy has drastically declined. \u201cWe have moved away from using chemotherapy for most patients, just over the last 5 years\u201d, Jan Burger, MD, PhD, of the department of leukemia at the University of Texas MD Anderson Cancer Center in Houston, told\u00a0Hematology Advisor<\/em>.<\/p>\n

\u201cWe now have good alternatives to chemotherapy that, in the end, have better survival rates for our patients\u201d Dr Burger, who is the author of the review paper, continued. \u201cThe reason why we were able to make this big step forward in treatment was to some extent [serendipitous]. These new kinase inhibitors became available at a time when there was more basic research which emphasized how important these molecules are in leukemia cells.\u201d<\/p>\n

To continue reading this article on Hematology Advisor\u00a0<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

CLL proliferate in secondary lymphatic organs where cancer cells engage in molecular and cellular interactions disrupting the adaptive immune response.<\/p>\n","protected":false},"author":1,"featured_media":14736,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17,23],"tags":[],"class_list":["post-14735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured","category-research"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/09\/Capture-cll.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14735"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14735\/revisions"}],"predecessor-version":[{"id":14737,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14735\/revisions\/14737"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/14736"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}